Sentence examples similar to discontinuation driven from inspiring English sources

For laboratory adverse event discontinuations, etoricoxib was associated with significantly fewer than was NSAIDs in trials of longer duration (NNTp 49), with laboratory adverse event discontinuations driven largely by elevated liver enzymes with diclofenac, which is the only NSAID used in the longer duration trials.

However, a recent study that included patients who were less severely ill demonstrated that continuation and discontinuation appear driven by the medication's efficacy for improving positive symptoms [ 30].

In the STRATEGY-PI study, there were significantly more treatment failures in patients continuing an LPV/r, ATV/r, or DRV/r-containing regimen than those switching to TDF/FTC/elvitegravir/cobicistat (EVG/c) (13 vs. 6 %; p = 0.025), the difference driven by discontinuations for non-virologic reasons.

Differences in overall discontinuation rate across studies appeared to be driven primarily by higher rates of discontinuation due to lack of efficacy in the oral olanzapine studies 1 and 3 relative to the olanzapine LAI study.

7 Others have reported the greater discontinuation rates on infliximab to be driven only by adverse events, specifically infusion and systemic allergic reactions.

This result was largely driven by lack of efficacy discontinuation, which for placebo constitutes 72% of all discontinuations.

Discontinuation was greater with placebo versus budesonide/formoterol and formoterol driven by withdrawal of consent.

If confirmed clinically, these findings could help inform decisions regarding discontinuation or changes in treatment, particularly since the increased FDG uptake is driven by metabolic changes that accelerate tumor growth rather than simply resulting in a lack of any response.

The ruxolitinib discontinuation data may also drive the choice of initial therapy in certain situations.

Our previous research [ 14] has suggested that although treatment discontinuation for any cause (switch or discontinuation) is an important proxy measure of a medication's effectiveness, the differences between antipsychotic medications on this proxy measure may be primarily driven by switching of the medication (when switching is a study option) rather than discontinuation.

The results of the model are driven by many different input parameters, including the probabilities of death, remission, relapse, recurrence, discontinuation and adverse event for each therapy option, as well as the corresponding utility values and cost associated with each health state.